These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 32881416)

  • 1. Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports.
    Fernandez S; Lenoir C; Samer C; Rollason V
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00647. PubMed ID: 32881416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase.
    Fernandez S; Lenoir C; Samer CF; Rollason V
    J Pers Med; 2021 Mar; 11(4):. PubMed ID: 33808367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apixaban - Metabolism, Pharmacologic Properties and Drug Interactions.
    Kubisz P; Stanciakova L; Dobrotova M; Samos M; Mokan M; Stasko J
    Curr Drug Metab; 2017; 18(7):609-621. PubMed ID: 28440204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia.
    Gomez-Lumbreras A; Cortes J; Giner-Soriano M; Quijada-Manuitt MA; Morros R
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):494-501. PubMed ID: 29792125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of apixaban for venous and arterial thromboembolic disease.
    Prom R; Spinler SA
    Ann Pharmacother; 2011 Oct; 45(10):1262-83. PubMed ID: 21954450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding.
    Hanigan S; Das J; Pogue K; Barnes GD; Dorsch MP
    J Thromb Thrombolysis; 2020 May; 49(4):636-643. PubMed ID: 31925665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database.
    Strandell J; Wahlin S
    Eur J Clin Pharmacol; 2011 Jun; 67(6):633-41. PubMed ID: 21253716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of
    Skripka AI; Krupenin PM; Kozhanova ON; Kudryavtseva AA; Fedina LV; Akmalova KA; Bochkov PO; Sokolova AA; Napalkov DA; Sychev DA
    Drug Metab Pers Ther; 2024 Jun; 39(2):89-97. PubMed ID: 38943286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A.
    Otsuka Y; Choules MP; Bonate PL; Komatsu K
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):659-669. PubMed ID: 33030266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation.
    Ueshima S; Hira D; Kimura Y; Fujii R; Tomitsuka C; Yamane T; Tabuchi Y; Ozawa T; Itoh H; Ohno S; Horie M; Terada T; Katsura T
    Br J Clin Pharmacol; 2018 Jun; 84(6):1301-1312. PubMed ID: 29457840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.
    Hult S; Sartori D; Bergvall T; Hedfors Vidlin S; Grundmark B; Ellenius J; Norén GN
    Drug Saf; 2020 Aug; 43(8):775-785. PubMed ID: 32681439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor.
    Frost CE; Byon W; Song Y; Wang J; Schuster AE; Boyd RA; Zhang D; Yu Z; Dias C; Shenker A; LaCreta F
    Br J Clin Pharmacol; 2015 May; 79(5):838-46. PubMed ID: 25377242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
    Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
    Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
    Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
    Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.
    Chang M; Yu Z; Shenker A; Wang J; Pursley J; Byon W; Boyd RA; LaCreta F; Frost CE
    J Clin Pharmacol; 2016 May; 56(5):637-45. PubMed ID: 26358690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Implications of Co-administering Apixaban with Key Interacting Medications.
    Favatella N; Dalton D; Byon W; Merali SJ; Klem C
    Clin Pharmacol Drug Dev; 2024 Sep; 13(9):961-973. PubMed ID: 39046333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
    Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
    Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database.
    Barbieri MA; Cutroneo PM; Baratelli C; Cicala G; Battaglia A; Santoro V; Andò G; Spina E
    J Clin Pharm Ther; 2021 Aug; 46(4):1027-1040. PubMed ID: 33646603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase.
    Strandell J; Caster O; Bate A; Norén N; Edwards IR
    Drug Saf; 2011 Mar; 34(3):253-66. PubMed ID: 21332249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.